Cargando…
Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
Human tumors develop multiple strategies to evade recognition and efficient suppression by the immune system. Therefore, a variety of immunotherapeutic strategies have been developed to reactivate and reorganize the human immune system. The recent development of new antibodies against immune check p...
Autores principales: | Moehler, Markus, Goepfert, Katrin, Heinrich, Bernd, Breitbach, Caroline J., Delic, Maike, Galle, Peter Robert, Rommelaere, Jean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013456/ https://www.ncbi.nlm.nih.gov/pubmed/24822170 http://dx.doi.org/10.3389/fonc.2014.00092 |
Ejemplares similares
-
Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells
por: Heinrich, Bernd, et al.
Publicado: (2013) -
Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
por: Meyers, Daniel E., et al.
Publicado: (2017) -
Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing
por: Goepfert, Katrin, et al.
Publicado: (2019) -
The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers
por: Angelova, Assia L., et al.
Publicado: (2017) -
Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1
por: Moehler, Markus, et al.
Publicado: (2011)